177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
Recruiting · NCT04903899 · Registry updated 2025-02-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2025-02-11 | NCT04903899 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Advanced Accelerator Applications | 11 |
| Jakob Stenman | 1 |
| Novartis | 114 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Karolinska University Hospital | Stockholm | Sweden | 1 |
| Oslo University Hospital, Rikshospitalet | Oslo | Norway | 1 |
| Princess Maxima Center for Pediatric Oncology | Utrecht | Netherlands | 1 |
| Rigshospitalet | Copenhagen | Denmark | 1 |
| Vilnius University Hospital | Vilnius | Lithuania | 1 |